Why Are InMed Pharmaceuticals Stock Trading Lower Today
Portfolio Pulse from Vandana Singh
InMed Pharmaceuticals' stock is trading lower after releasing safety and efficacy results from its Phase 2 clinical trial for symptoms related to Epidermolysis Bullosa (EB). The trial showed mixed results, with some patients experiencing improvement with INM-755 cannabinol cream, while others did not. The company plans to seek R&D and commercial partnership opportunities for further development.
June 22, 2023 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
InMed Pharmaceuticals' stock is trading lower after mixed results from its Phase 2 clinical trial for INM-755 cannabinol cream. The company plans to seek partnerships for further development.
InMed Pharmaceuticals' stock is trading lower due to the mixed results from its Phase 2 clinical trial for INM-755 cannabinol cream. While some patients experienced improvement, others did not, which may have led to investor uncertainty. The company's plan to seek partnerships for further development may also contribute to the stock's short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100